Pulmatrix Inc ::PULMATRIX REPORTS Q2 2018 RESULTS.PULMATRIX INC - QTRLY LOSS PER SHARE $0.13.PULMATRIX INC - AS OF JUNE 30, 2018, PULMATRIX HAD $8.3 MILLION IN CASH AND CASH EQUIVALENTS.PULMATRIX INC QTRLY LOSS PER SHARE $0.13.
Full Article
July 17 (Reuters) - Pulmatrix Inc ::PULMATRIX ANNOUNCES POSITIVE TOP-LINE PRELIMINARY RESULTS FROM PART 3 OF THE 3-PART PHASE 1/1B CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE.ALL OBJECTIVES FROM PART 3 SUCCESSFULLY MET.WITH PHASE 1/1B RESULTS FROM PART 3 NOW ALSO IN HAND, PULMATRIX PLANS TO INITIATE A PHASE 2 TRIAL IN ABPA PATIENTS IN Q4 2018.PULMAZOLE WAS SAFE AND WELL TOLERATED ADMINISTERED AS A SINGLE-DOSE OF 20 MG INHALED ITRACONAZOLE IN ASTHMATIC SUBJECTS.
Full Article
Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly net loss per share attributable to common stockholders $0.22.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016.
Full Article
Earnings vs. 
Estimates